Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus H R 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus H R 50.
DEPO-TESTOSTERONE vs H.R.-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
50-400 mg IM every 2-4 weeks
12.5 mg orally twice daily
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Category D/X
Category C
Androgen
Androgen